RESEARCH HIGHLIGHT 01 December 2023

The SARS-CoV-2 main protease (Mpro) is an attractive antiviral target due to its indispensable role in viral replication, high degree of conservation across coronaviruses, and low homology with human proteases. Indeed, first generation oral Mpro inhibitors, such as nirmatrelvir, have demonstrated clinical efficacy. However, as co-dosing with a cytochrome P450 3A4 inhibitor (such as ritonavir) is required to achieve adequate exposure, this may limit use in some patients due to drug–drug interactions. There is therefore a need for novel, chemically different, oral antiviral protease inhibitors.

Access options

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

24,99 € / 30 days

cancel any time

Subscription info for Chinese customers

We have a dedicated website for our Chinese customers. Please go to naturechina.com to subscribe to this journal.

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

doi: https://doi.org/10.1038/d41573-023-00195-6

Jobs